Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Exploring Selenium-Functionalized Hydroxyapatite Using Organic Selenocystine for Antitumor Applications

Barbanente A., Di Cosola AM., Degli Esposti L., Iafisco M., Niso M., Margiotta N.

Laboratory Study, published in Materials (Basel) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Materials (Basel) (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40077269
PMCID
PMC11901003
DOI
10.3390/ma18051043

Abstract (original English)

Selenium (Se) is an essential micronutrient, recognized for its role in cellular redox systems and its therapeutic potential in cancer treatment. Organic selenium compounds, particularly selenocystine (SeCys), have demonstrated anticancer efficacy due to the ability to induce apoptosis and enhance the effects of chemotherapy agents. Recent studies have shown that SeCys exhibits selective toxicity against cancer cells while sparing normal cells. Unfortunately, its clinical application is limited by stability and solubility concerns. A possible solution to overcome these hurdles comes from recent advances in functionalized nanomaterials. In this study, we investigate the possible incorporation of SeCys with hydroxyapatite nanoparticles (HASeCys) via various methods (adsorption, co-precipitation, and co-precipitation through thermal decomplexation), resulting in the formation of nanocomposites with elemental selenium. The highest elemental selenium yield was achieved with a thermal decomplexing co-precipitation, highlighting the influence of synthesis parameters on Se allotrope formation. Finally, as a preliminary investigation, the HASeCys samples were tested on a panel of cancer cell lines, showing an interesting activity when the hydroxyapatite nanocrystals were functionalized with both crystalline gray and amorphous red selenium.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.